IMMX — Immix Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $473.50m
- $373.09m
Annual cashflow statement for Immix Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.4 | -8.23 | -15.6 | -21.7 | -29.4 |
| Depreciation | |||||
| Non-Cash Items | 23.2 | 0.624 | 2.57 | 3.1 | 2.56 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.391 | 0.195 | 1.65 | 3.97 | 2.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.59 | -7.41 | -11.4 | -14.6 | -23.9 |
| Capital Expenditures | -0.001 | 0 | -0.052 | -1.18 | -0.733 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -6.48 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.001 | 0 | -0.052 | -1.18 | -7.21 |
| Financing Cash Flow Items | — | 0.468 | -0.235 | — | -0.137 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.8 | 3.23 | 15.5 | 15.9 | 107 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 17.3 | -4.21 | 4.07 | 0.172 | 76.2 |